Bausch + Lomb Corporation, a subsidiary of Bausch Health, and AcuFocus, Inc. announced on January 17 that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
BofA Securities served as exclusive financial advisor to AcuFocus. Norton Rose Fulbright served as legal advisor to Bausch + Lomb, and Latham & Watkins LLP served as legal advisor to AcuFocus. Financial terms of the deal were not disclosed.
AcuFocus is a privately held ophthalmic medical device company based in Irvine, California. AcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care, including the IC-8® Apthera™ intraocular lens, which was approved by the U.S. Food and Drug Administration in July 2022 for the treatment of cataracts.
Bausch + Lomb provides healthcare products for the eye in three business segments: vision care, pharmaceuticals and surgical. Its portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.
According to data captured from the LevinPro HC database, this transaction represents the ninth Medical Devices deal of 2023. There were 120 Medical Devices transactions in 2022.
